Summary

Global Cystic Fibrosis Therapeutics Market is valued approximately at USD 9.02 billion in 2023 and is projected to witness a remarkable CAGR of more than 14.20% during the forecast period 2024–2032. Cystic fibrosis, a life-threatening genetic disorder that critically impacts respiratory and digestive systems, has long challenged both patients and providers due to its progressive nature and limited curative options. However, the pharmaceutical landscape for cystic fibrosis is undergoing a radical transformation, steered by innovative therapies designed to address the root causes of the disease rather than merely alleviating symptoms. Pancreatic enzyme supplements, which help restore digestive efficiency, continue to dominate the therapeutic approach. Meanwhile, the growing preference for oral drug administration is accelerating adoption among patients and caregivers, given its convenience and improved adherence rates.
The robust growth of this market is underpinned by multiple synergistic forces, including increased diagnosis rates due to expanded newborn screening programs and a surge in research funding for rare genetic disorders. Breakthroughs in gene-targeted drugs and personalized medicine are shifting the treatment paradigm from symptomatic management to precision-targeted solutions. Moreover, biotechnology firms are increasingly investing in next-generation modulators that correct the defective CFTR protein responsible for cystic fibrosis. However, pricing pressures, reimbursement hurdles, and unequal access to advanced drugs in low- and middle-income countries remain persistent barriers to universal treatment availability. These challenges are being gradually addressed through global health partnerships and strategic regulatory support aimed at fast-tracking essential drug approvals.
R&D pipelines are teeming with novel small molecule drugs and triple combination therapies that promise to treat a broader segment of the cystic fibrosis population, including patients with rare mutations. Regulatory bodies such as the FDA and EMA have prioritized cystic fibrosis drug approvals, recognizing the urgent unmet need. Parallel to pharmaceutical advancements, supportive care involving dietary management and digital adherence tools is being integrated into treatment regimens, thus fostering a holistic approach to disease management. Additionally, the push toward value-based healthcare models is nudging manufacturers to demonstrate real-world efficacy and long-term cost savings, fostering a more sustainable ecosystem for therapeutic innovation.
North America currently holds the lion’s share of the cystic fibrosis therapeutics market, buoyed by advanced healthcare infrastructure, favorable reimbursement frameworks, and the strong presence of pioneering biotech firms. The United States, in particular, continues to be the nucleus for clinical trials and new drug launches. Europe follows closely, especially in countries like Germany, the UK, and France, where early diagnosis programs and national cystic fibrosis registries are well established. The Asia Pacific region is emerging as a high-growth zone, propelled by increasing awareness, growing investments in rare disease research, and government-led healthcare expansions in countries such as India, China, and Australia. Latin America and the Middle East & Africa are also expected to witness upward trends as awareness campaigns, donor funding, and access initiatives gain traction.
Major market player included in this report are:
• AbbVie Inc.
• Vertex Pharmaceuticals Inc.
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Chiesi Farmaceutici S.p.A.
• AstraZeneca plc
• Pharmaxis Ltd.
• Allergan plc
• Alcresta Therapeutics Inc.
• Santhera Pharmaceuticals
• Genentech, Inc.
• Nestlé Health Science
• Mylan N.V.
The detailed segments and sub-segment of the market are explained below:
By Drug Class
• Pancreatic Enzyme Supplements
By Route of Administration
• Oral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Cystic Fibrosis Therapeutics Market Executive Summary
1.1. Global Cystic Fibrosis Therapeutics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Route of Administration
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Cystic Fibrosis Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Raw Material & Enzyme Availability
2.3.3.2. Manufacturing Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Manufacturer Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Patient Awareness & Diagnosis Rates
2.3.4.2. Reimbursement Frameworks
2.3.4.3. Technological Advancements in Oral Formulations
2.3.4.4. Caregiver Adoption & Adherence
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Cystic Fibrosis Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Expanded Newborn Screening Programs
3.1.2. Surge in Gene-Targeted and Modulator Therapies
3.1.3. Rising Investment in Rare Disease R&D
3.2. Market Challenges
3.2.1. High Cost of Advanced Modulators
3.2.2. Reimbursement and Pricing Pressures
3.2.3. Limited Access in Emerging Economies
3.3. Market Opportunities
3.3.1. Growth of Triple Combination Regimens
3.3.2. Expansion of Oral Enzyme Supplements
3.3.3. Digital Adherence and Support Tools
Chapter 4. Global Cystic Fibrosis Therapeutics Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Cystic Fibrosis Therapeutics Market Size & Forecasts by Drug Class (2022–2032)
5.1. Segment Dashboard
5.2. Pancreatic Enzyme Supplements: Revenue Trend Analysis, 2022 & 2032
Chapter 6. Global Cystic Fibrosis Therapeutics Market Size & Forecasts by Route of Administration (2022–2032)
6.1. Segment Dashboard
6.2. Oral: Revenue Trend Analysis, 2022 & 2032
Chapter 7. Global Cystic Fibrosis Therapeutics Market Size & Forecasts by Distribution Channel (2022–2032)
7.1. Segment Dashboard
7.2. Hospital Pharmacies, Retail Pharmacies & Online Pharmacies: Revenue Trend Analysis, 2022 & 2032
Chapter 8. Global Cystic Fibrosis Therapeutics Market Size & Forecasts by Region (2022–2032)
8.1. North America Market
8.1.1. U.S. Market
8.1.1.1. Drug Class Breakdown & Forecasts, 2022–2032
8.1.1.2. Distribution Channel Breakdown & Forecasts, 2022–2032
8.1.2. Canada Market
8.2. Europe Market
8.2.1. UK Market
8.2.2. Germany Market
8.2.3. France Market
8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific Market
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of APAC Market
8.4. Latin America Market
8.4.1. Brazil Market
8.4.2. Mexico Market
8.4.3. Rest of LATAM Market
8.5. Middle East & Africa Market
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of MEA Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. AbbVie Inc.
9.1.2. Vertex Pharmaceuticals Inc.
9.1.3. Gilead Sciences, Inc.
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. AbbVie Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Vertex Pharmaceuticals Inc.
9.3.3. Gilead Sciences, Inc.
9.3.4. F. Hoffmann-La Roche Ltd.
9.3.5. Novartis AG
9.3.6. Teva Pharmaceutical Industries Ltd.
9.3.7. Chiesi Farmaceutici S.p.A.
9.3.8. AstraZeneca plc
9.3.9. Pharmaxis Ltd.
9.3.10. Allergan plc
9.3.11. Alcresta Therapeutics Inc.
9.3.12. Santhera Pharmaceuticals
9.3.13. Genentech, Inc.
9.3.14. Nestlé Health Science
9.3.15. Mylan N.V.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes